EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?

Míreanna Comhchosúla

• Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
  le: Gelatti, Ana, et al.
  Foilsithe: (2019)
• Adjuvant EGFR-TKIs-based therapy: are we ready?
  le: Tam, Terence
  Foilsithe: (2020)
• Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
  le: Lemmon, Christopher, et al.
  Foilsithe: (2020)
• The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
  le: Lin, Chutong, et al.
  Foilsithe: (2021)
• Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles
  le: Parris, Brielle A., et al.
  Foilsithe: (2021)